Interestingly, we observed moderate but statistically significantly higher expression of LXN both in both ES and MS samples of patients compared to healthy women (2.0-fold and 1.9-fold, respectively, one-way ANOVA both p < 0.0001). The gene discussed is LXN; the disease is myeloid sarcoma.